Trial Profile

First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium-68 NOTA hGZP (Primary)
Indications Cancer; Malignant melanoma; Non-small cell lung cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Cytosite Bio

Most Recent Events

28 Nov 2022 According to a Cytosite Bio media release, results from this trial were presented at the Radiological Society of North American (RSNA) Annual Meeting 2022.
28 Nov 2022 Results (n=8) published in the Cytosite Bio Media Release.
01 Jun 2022 Planned number of patients changed from 20 to 30.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com